Skip to main content

Table 1 Sociodemographic and Clinical Characteristics (n = 220)

From: Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer’s disease: a prospective, observational study of factors affecting survival time from admission to death

  At the start of ChEI treatment At nursing-home placementa
Variable n/% n/%
Female sex 161/73 % na
APOE genotype, (n = 208)   na
 No ε4 alleles 57/27 %  
 One ε4 allele 118/57 %  
 Two ε4 alleles 33/16 %  
Solitary living 116/53 % 126/57 %
Antihypertensive/cardiac therapy 79/36 %  
Antidiabetics 9/4 %  
Asthma medication 9/4 %  
Thyroid therapy 19/9 %  
Lipid-lowering agents 15/7 %  
Estrogens 17/8 %  
NSAIDs/acetylsalicylic acid 63/29 %  
Antidepressants 71/32 %  
Antipsychotics 14/6 %  
Anxiolytics/sedatives/hypnotics 41/19 %  
Variable Mean ± standard deviation
Estimated age at onset of AD, years 73.5 ± 6.9 na
Estimated duration of AD, years 3.4 ± 2.6 5.1 ± 2.7
Age, years 76.9 ± 5.9 78.6 ± 5.8
Education, years 9.2 ± 2.3 na
MMSE score 20.1 ± 4.0 17.5 ± 5.7
ADAS-cog score (0–70) 24.0 ± 9.7 29.2 ± 12.5
IADL score 18.3 ± 5.1 22.7 ± 4.7
PSMS score 8.2 ± 2.8 10.5 ± 3.9
Number of concomitant medicationsa 3.0 ± 2.4  
Home-help service, h/week 6.6 ± 5.4
(n = 56)
5.7 ± 6.5
(n = 180)
Adult day care, days/week 3.2 ± 1.7
(n = 23)
3.0 ± 1.4
(n = 82)
Mean dose of ChEI during the SATS, mg   
 Donepezil (n = 138) 6.8 ± 1.8 na
 Rivastigmine (n = 37) 5.7 ± 1.9 na
 Galantamine (n = 45) 15.1 ± 3.2 na
Time to nursing home placement from the start of ChEI therapy, months 19.5 ± 10.0 na
Age at death, years 82.6 ± 6.0 na
  1. AD Alzheimer’s disease, ADAS-cog Alzheimer’s Disease Assessment Scale – cognitive subscale, APOE apolipoprotein E, ChEI cholinesterase inhibitor, IADL Instrumental Activities of Daily Living scale, MMSE Mini-Mental State Examination, na not applicable, NSAIDs nonsteroidal anti-inflammatory drugs, PSMS Physical Self-Maintenance Scale, SATS Swedish Alzheimer Treatment Study
  2. aConcomitant medications were not recorded at the postbaseline visits